Haemonetics Co. (HAE) Holdings Trimmed by Oberweis Asset Management Inc.

Share on StockTwits

Oberweis Asset Management Inc. reduced its stake in shares of Haemonetics Co. (NYSE:HAE) by 23.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 40,535 shares of the medical instruments supplier’s stock after selling 12,365 shares during the quarter. Oberweis Asset Management Inc. owned 0.08% of Haemonetics worth $4,056,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of HAE. Financial Gravity Companies Inc. acquired a new stake in shares of Haemonetics in the fourth quarter valued at approximately $41,000. We Are One Seven LLC purchased a new position in shares of Haemonetics during the fourth quarter valued at approximately $51,000. Hanseatic Management Services Inc. lifted its stake in shares of Haemonetics by 8,500.0% during the fourth quarter. Hanseatic Management Services Inc. now owns 1,462 shares of the medical instruments supplier’s stock valued at $146,000 after buying an additional 1,445 shares during the period. Ffcm LLC lifted its stake in shares of Haemonetics by 134.4% during the fourth quarter. Ffcm LLC now owns 1,744 shares of the medical instruments supplier’s stock valued at $174,000 after buying an additional 1,000 shares during the period. Finally, Jefferies Group LLC purchased a new position in shares of Haemonetics during the third quarter valued at approximately $230,000. Institutional investors own 98.13% of the company’s stock.

In other news, Director Ronald G. Gelbman sold 8,196 shares of the firm’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $86.52, for a total value of $709,117.92. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Michelle L. Basil sold 391 shares of the firm’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $83.57, for a total transaction of $32,675.87. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,703 shares of company stock worth $751,488. 1.04% of the stock is currently owned by insiders.

NYSE:HAE traded up $0.30 during trading hours on Friday, reaching $87.05. 890 shares of the company were exchanged, compared to its average volume of 456,746. The company has a quick ratio of 1.64, a current ratio of 2.44 and a debt-to-equity ratio of 0.51. The company has a market cap of $4.43 billion, a P/E ratio of 46.51, a P/E/G ratio of 2.80 and a beta of 0.89. Haemonetics Co. has a 52-week low of $70.86 and a 52-week high of $117.56.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $0.63 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.04. The company had revenue of $247.36 million for the quarter, compared to the consensus estimate of $250.12 million. Haemonetics had a net margin of 4.84% and a return on equity of 17.05%. Haemonetics’s revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 earnings per share. Research analysts forecast that Haemonetics Co. will post 2.33 earnings per share for the current fiscal year.

Several equities analysts recently issued reports on the stock. ValuEngine downgraded shares of Haemonetics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 5th. Barrington Research upped their price objective on shares of Haemonetics to $112.00 and gave the company a “positive” rating in a research note on Wednesday, February 6th. Finally, Zacks Investment Research downgraded shares of Haemonetics from a “buy” rating to a “sell” rating in a research note on Tuesday, January 8th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $119.75.

TRADEMARK VIOLATION NOTICE: “Haemonetics Co. (HAE) Holdings Trimmed by Oberweis Asset Management Inc.” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4223785/haemonetics-co-hae-holdings-trimmed-by-oberweis-asset-management-inc.html.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Article: What are the benefits of a balanced fund?

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mitie Group PLC  Receives Consensus Recommendation of “Buy” from Brokerages
Mitie Group PLC Receives Consensus Recommendation of “Buy” from Brokerages
Critical Comparison: Weatherford International  versus Its Peers
Critical Comparison: Weatherford International versus Its Peers
Sanford C. Bernstein Analysts Give Beiersdorf  a €91.00 Price Target
Sanford C. Bernstein Analysts Give Beiersdorf a €91.00 Price Target
Wolverine World Wide  Downgraded by ValuEngine
Wolverine World Wide Downgraded by ValuEngine
Dycom Industries  Stock Rating Lowered by ValuEngine
Dycom Industries Stock Rating Lowered by ValuEngine
FY2020 EPS Estimates for Innergex Renewable Energy Inc  Lowered by Raymond James
FY2020 EPS Estimates for Innergex Renewable Energy Inc Lowered by Raymond James


© 2006-2019 Ticker Report